Foghorn Therapeutics Inc.
FHTX
$5.41
-$0.12-2.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.71% | 17.86% | -50.49% | -55.33% | 23.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.71% | 17.86% | -50.49% | -55.33% | 23.02% |
| Cost of Revenue | -8.43% | -15.31% | -15.27% | -5.95% | -18.64% |
| Gross Profit | 15.81% | 23.48% | 4.25% | -92.42% | 28.50% |
| SG&A Expenses | -6.32% | -6.11% | -9.53% | -16.09% | -12.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.93% | -13.17% | -13.98% | -8.39% | -17.34% |
| Operating Income | 12.94% | 18.73% | 5.71% | -39.64% | 24.39% |
| Income Before Tax | 21.95% | 24.71% | 11.83% | -40.53% | 19.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 21.95% | 24.71% | 19.09% | -33.30% | 22.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.95% | 24.71% | 19.09% | -33.30% | 22.07% |
| EBIT | 12.94% | 18.73% | 5.71% | -39.64% | 24.39% |
| EBITDA | 13.64% | 19.27% | 5.54% | -42.56% | 24.80% |
| EPS Basic | 36.07% | 49.17% | 45.66% | 10.52% | 36.81% |
| Normalized Basic EPS | 28.63% | 49.17% | 40.78% | 5.68% | 41.52% |
| EPS Diluted | 36.07% | 49.17% | 45.66% | 10.52% | 36.81% |
| Normalized Diluted EPS | 28.63% | 49.17% | 40.78% | 5.68% | 41.52% |
| Average Basic Shares Outstanding | 22.10% | 48.13% | 48.87% | 48.96% | 23.32% |
| Average Diluted Shares Outstanding | 22.10% | 48.13% | 48.87% | 48.96% | 23.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |